Study on the Safety and Effectiveness of CAB-AXL-ADC in Adults with Non-Small Cell Lung Cancer (NSCLC)

Sponsor: BioAtla, Inc.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04681131

Provider View

This clinical trial is testing a new treatment called CAB-AXL-ADC to see if it is safe and effective for adults with metastatic non-small cell lung cancer (NSCLC). The study will also explore how the treatment works when used alone or with another drug that helps the immune system fight cancer.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the safety and effectiveness of a new treatment called CAB-AXL-ADC in adults with metastatic non-small cell lung cancer (NSCLC). Researchers will look at how well the treatment works on its own and in combination with a drug that boosts the immune system. The study will take place at multiple locations and will involve monitoring the treatment's effects on the body, including its safety, how the body processes it, and its ability to fight cancer.

Description

This study is a Phase 2 trial conducted at several centers to assess the safety and effectiveness of CAB-AXL-ADC, a new type of cancer treatment. CAB-AXL-ADC is a specially designed drug that targets cancer cells in non-small cell lung cancer (NSCLC). The study will test the drug both by itself and in combination with a PD-1 inhibitor, which is a medication that helps the immune system attack cancer cells. Participants will be monitored for how well they tolerate the treatment, how their body processes it, and its impact on their cancer.

Eligibility Criteria

Inclusion Criteria

  • Must have cancer that can be measured by doctors.
  • Must be 18 years or older.
  • Must have good kidney function.
  • Must have good liver function.
  • Must have healthy blood cell levels.
  • Must be in good general health, able to carry out normal activities or only slightly restricted.
  • Must have a life expectancy of at least three months.

Exclusion Criteria

  • Must not have serious heart problems.
  • Must not have uncontrolled cancer that has spread to the brain.
  • Must not have had previous treatment with certain types of cancer drugs.
  • Must not have had severe allergic reactions to similar treatments or be allergic to any study medications.
  • Must not have had major surgery within four weeks before starting the study treatment.
  • Must not have HIV, active hepatitis B, or hepatitis C infections.
  • Must not be pregnant or breastfeeding.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.